A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

Brief summary (registry, in English)

-To evaluate if the 10-week induction efficacy of LY4268989 is superior to placebo as assessed by clinical remission in participants with moderately to severely active UC -To evaluate if the maintenance efficacy of LY4268989 is superior to placebo at Week 52 (Visit 208) as assessed by clinical remission among participants who achieve clinical response with LY4268989 at Week 10

What you commit to

• Study type: Interventional · Phase 2
• Planned participants: 104
• 61 sites in 11 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderately to severely active ulcerative colitis who did not respond well to, lost response to, or could not tolerate earlier treatment.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Ulcerative colitis diagnosed at least 3 months ago, moderately to severely active (Modified Mayo Score 5 to 9, Endoscopic Score of at least 2, rectal bleeding of at least 1), reaching beyond the rectum.

Earlier treatment

Inadequate response, loss of response or intolerance to at least one conventional medicine (including corticosteroids) or one advanced therapy (biologics, JAK inhibitors or S1P immunomodulators). People with inadequate response to vedolizumab cannot join.

Main reasons for not taking part

• Crohn's disease, unclassified inflammatory bowel disease or primary sclerosing cholangitis
• Inherited immune deficiency or a known single-gene cause of colitis
• Bowel resection or intestinal or abdominal surgery, past or needed
• Toxic megacolon, abdominal abscess, or narrowing of the bowel
• Cancer of the digestive tract, or other cancer within 5 years before randomization

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (61)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details